Ocugen Schedules March 24 Webcast for Full OCU410 Phase 2 Data
Ocugen, Inc. (NASDAQ: OCGN) will host a conference call on March 24, 2026, at 8:00 a.m. EDT (UTC-4) to present the complete dataset from its Phase 2 ArMaDa trial for OCU410. This gene therapy candidate targets geographic atrophy (GA), an advanced form of dry age-related macular degeneration (dAMD). The announcement on March 23 positions the webcast as a crucial event for investors, with the stock's direction hinging on the trial's outcome.
Data Builds on Preliminary 46% Lesion Growth Reduction
OCU410 is a cornerstone of Ocugen's modifier gene therapy platform, which seeks to treat complex diseases with multiple genetic causes rather than targeting a single mutation. For geographic atrophy, OCU410 aims to address multiple disease pathways, a contrast to the single-pathway anti-complement therapy currently available in the U.S. There are no approved treatments for GA in Europe, highlighting the significant unmet medical need.
Investors are anticipating confirmation of earlier promising signals after preliminary Phase 2 data showed OCU410 produced a 46% reduction in lesion growth at 12 months in medium- and high-dose groups. A strong final dataset could validate the platform's potential and provide a new therapeutic option for a broad patient population.
Analysts Bullish Ahead of 2026-2027 Catalyst Pipeline
The data release occurs within a context of growing analyst confidence. Oppenheimer recently initiated coverage with an "Outperform" rating and a $10 price target, while Chardan Capital holds a "Buy" rating with a $7 target. This optimism persists despite the company's financial position, which includes a reported net loss of $67.8 million for 2025 and reliance on a $22.5 million capital raise in January 2026 to fund operations.
The OCU410 results are the first in a series of major catalysts for Ocugen. The company also plans a rolling Biologics License Application (BLA) for its retinitis pigmentosa therapy, OCU400, in the third quarter of 2026, with top-line Phase 3 data expected in the first quarter of 2027. These upcoming milestones make the OCU410 data readout a critical indicator of the company's ability to execute its ambitious clinical and regulatory strategy.
